Mid Atlantic Retina is pleased that the FDA has approved gene therapy, voretigene (Luxturna), for very specific uncommon genetic retinal diseases, caused by mutations in the gene RPE65 which may cause a form of Leber Congenital Amaurosis or retinitis pigmentosa. These disorders cause severe loss of vision starting at birth or in early childhood. Not... read more
Dr Carl Regillo remarks on PhaseII Study for Dry AMD and Mid Atlantic Retina/Wills Eye Hospitals participation in the clinical trials. Click here to read more.